tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2018-8-1-22-29tumors-492Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL REPORTSМорфологические и иммунологические особенности стимулированного Г-КСФ аутологичного и аллогенного костного мозга, применяемого для трансплантации в клинической онкологииMorphological and immunological features of G-CSF-stimulated autologous and allogeneic bone marrow, which is used for transplantation in clinical oncologyГривцоваЛ. Ю.GrivtsovaL. Yu.

к. м. н., с. н. с., лаборатория иммунологии гемопоэза

MD, PhD Med, Senior Researcher, Haematopoiesis Immunology Lab.

grivtsova@mail.ruЧернявскаяТ. З.CherniavskayaT. Z.

врач-трансплантолог, отделение интенсивной терапии и реанимации с трансплантацией костного мозга

MD, transplantologist, Department of Intensive Chemotherapy and Reanimation with Bone Marrow Transplantation

МелковаК. Н.MelkovaK. N.

к. м. н., зав. отделением, отделение интенсивной терапии и реанимации с трансплантацией костного мозга

MD, PhD Med, Head of the Department of Intensive Chemotherapy and Reanimation with Bone Marrow Transplantation

КолбацкаяО. П.KolbatskayaO. P.

к. м. н., научный сотрудник, лаборатория иммунологии гемопоэза

MD, PhD Med, Researcher, Haematopoiesis Immunology Lab.

КупрышинаН. А.KupryshinaN. A.

к. м. н., с. н. с., лаборатория иммунологии гемопоэза

MD, PhD Med, Senior Researcher, Haematopoiesis Immunology Lab.

ВоротниковИ. К.VorotnikovI. K.

д. м. н., профессор, зав. отделением, отделение опухолей молочных желез

MD, DSc Med, Professor, Head of the Department of Breast Cancer

ГригорьеваТ. А.GrigorievaT. A.

к. м. н., кафедра онкологии

MD, PhD Med, Faculty of Oncology

СельчукВ. Ю.SelchukV. Yu.

д. м. н., профессор, зав. кафедрой, кафедра онкологии

MD, DSc Med, Professor, Head of the Faculty of Oncology

ТупицынН. Н.TupitsynN. N.

д. м. н., профессор, зав. лабораторией, лаборатория иммунологии гемопоэза

MD, DSc Med, Professor, Head of the Haematopoiesis Immunology Lab.

НИИ КО ФГБУ «НМИЦ онкологии им. Н. Н. Блохина» Министерства здравоохранения РФРоссияN. N. Blokhin Russian Cancer Research CenterRussian FederationГБОУ ВПО МГМСУ им. А. И. Евдокимова Министерства здравоохранения РФРоссияA. I. Evdokimov Moscow State Medical Stomatology UniversityRussian Federation201810052018812229Copyright © Гривцова Л.Ю., Чернявская Т.З., Мелкова К.Н., Колбацкая О.П., Купрышина Н.А., Воротников И.К., Григорьева Т.А., Сельчук В.Ю., Тупицын Н.Н., 20182018Гривцова Л.Ю., Чернявская Т.З., Мелкова К.Н., Колбацкая О.П., Купрышина Н.А., Воротников И.К., Григорьева Т.А., Сельчук В.Ю., Тупицын Н.Н.Grivtsova L.Y., Cherniavskaya T.Z., Melkova K.N., Kolbatskaya O.P., Kupryshina N.A., Vorotnikov I.K., Grigorieva T.A., Selchuk V.Y., Tupitsyn N.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/492

При анализе 58 образцов стимулированного костного мозга (39 онкологических больных и 19 здоровых доноров), полученного для трансплантации онкологическим больным, и сопоставлении основных показателей с исторической нормой и 13 образцами костного мозга больных контрольной группы (мастопатия) выявлен ряд особенностей стимулированного костного мозга. Показано достоверное увеличение количества бластных клеток костного мозга у онкологических больных в сравнении с донорами и группой контроля (р<0,037). В образцах стимулированного костного мозга (онкологические больные и доноры) выявлен более высокий индекс созревания нейтрофилов (р<0,001) и снижение процента зрелых лимфоцитов (p<0,008) в сравнении с контрольной группой. Среди лимфоцитарных популяций под влиянием ГКСФ как у онкологических больных, так и у доноров отмечено нарастание суммарного числа зрелых CD3+ Т-клеток и CD8+ Т-киллеров (p<0,0001), а также снижение количества субпопуляций NK-клеток CD56+ CD3–  и/или CD16+ CD3– (р<0,006) в сравнении с группой контроля.

58 samples of stimulated bone marrow (39 – oncology patients, 19 healthy donors) obtained for transplantation in cancer patients were analysed and compared to control group (13 bone marrow samples from women with mastopathies). It was noted the significant increase of blast cells in cancer patients compared to donors and control group (p<0.037). Neutrophyl maturation index was higher in stimulated bone marrow (p<0.001) and decrease of lymphocyte percentage (p<0.008) compared to control group: elevation of CD3+ and CD8+ lymphocytes (p<0.0001) as well as decrease of NK-cells CD56+ CD3-  and/ or CD16+ CD3-).

костный мозгстимуляция Г-КСФсубпопуляции лимфоцитовморфологияаутологичная и аллогенная трансплантацииbone marrowG-CSF-stimulationlymphocytes subpopulationmorphologyautologous and allogenic bone marrow transplantationReferencesAppelbaum F.R. Hematopoietic-cell transplantation at 50. The New England Journal of Medicine. 2007. Vol. 357 (15). P. 1472–1475.Appelbaum F.R. Hematopoietic-cell transplantation at 50. The New England Journal of Medicine. 2007. Vol. 357 (15). P. 1472–1475.Baldomero H., Gratwohl M., Gratwohl A., Tichelli A., Niederwieser D., Madrigal A. et al. The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplantation. 2011. Vol. 46 (4). P. 485–501.Baldomero H., Gratwohl M., Gratwohl A., Tichelli A., Niederwieser D., Madrigal A. et al. The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplantation. 2011. Vol. 46 (4). P. 485–501.Pasquini M.C., Zhu X. Current uses and outcomes of hematopoietic stem cell transplantation: 2014 CIBMTR Summary Slides. Available from: http://www.cibmtr.org 2014.Pasquini M.C., Zhu X. Current uses and outcomes of hematopoietic stem cell transplantation: 2014 CIBMTR Summary Slides. Available from: http://www.cibmtr.org 2014.Morton J., Hutchins Ch., Durrant S. Granulocyte – colony-stimulating factor (G-CSF) – primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF – mobilized peripheral blood stem cells. Blood. 2001. Vol. 98. P. 3186–3191.Morton J., Hutchins Ch., Durrant S. Granulocyte – colony-stimulating factor (G-CSF) – primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF – mobilized peripheral blood stem cells. Blood. 2001. Vol. 98. P. 3186–3191.Flowers M. E., Parker P.M., Johnston L. J. et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood. 2002. Vol. 100 (2). P. 415–419.Flowers M. E., Parker P.M., Johnston L. J. et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood. 2002. Vol. 100 (2). P. 415–419.Storek J., Gooley T., Siadak M. et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease [see comments]. Blood. 1997. Vol. 90. P. 4705–4709.Storek J., Gooley T., Siadak M. et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease [see comments]. Blood. 1997. Vol. 90. P. 4705–4709.Holtick U., Albrecht M., Chemnitz J.M. et al. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. Cochrane Database Syst. Rev. 2014. Vol. 4. CD010189.Holtick U., Albrecht M., Chemnitz J.M. et al. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. Cochrane Database Syst. Rev. 2014. Vol. 4. CD010189.Anasetti C., Logan B.R., Lee S. J. et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N. Engl. J. Med. 2012. Vol. 367 (16). P. 1487–1496.Anasetti C., Logan B.R., Lee S. J. et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N. Engl. J. Med. 2012. Vol. 367 (16). P. 1487–1496.Eapen M., Logan B.R., Horowitz M.M. et al. Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation. J. Clin. Oncol. 2015. Vol. 33 (4). P. 364–369.Eapen M., Logan B.R., Horowitz M.M. et al. Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation. J. Clin. Oncol. 2015. Vol. 33 (4). P. 364–369.Mackall C. L., Gress R. E. Pathways of T cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy. Immunol. Rev. 1997. Vol. 157. P. 61–72.Mackall C. L., Gress R. E. Pathways of T cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy. Immunol. Rev. 1997. Vol. 157. P. 61–72.Collins R.H. Jr., Shpilberg O., Drobyski W.R., Porter D. L., Giral S., Champlin R., Goodman S.A., Wolff S.N., Hu W., Verfaillie C. et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol. 1997. Vol. 15. P. 433–444.Collins R.H. Jr., Shpilberg O., Drobyski W.R., Porter D. L., Giral S., Champlin R., Goodman S.A., Wolff S.N., Hu W., Verfaillie C. et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol. 1997. Vol. 15. P. 433–444.Kolb H. J., Schattenberg A., Goldman J.M., Hertenstein B., Jacobsen N., Arcese W., Ljungman P., Ferrant A., Verdonck L., Niederwieser D. et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood. 1995. Vol. 86. P. 2041–2050.Kolb H. J., Schattenberg A., Goldman J.M., Hertenstein B., Jacobsen N., Arcese W., Ljungman P., Ferrant A., Verdonck L., Niederwieser D. et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood. 1995. Vol. 86. P. 2041–2050.Zheng H., Matte-Martone C., Jain Dh., McNiff J., Shlomchik W.D. Central Memory CD8_ T Cells Induce Graft-versus-Host Disease and Mediate Graft-versus-Leukemia. The Journal of Immunology. 2009. Vol. 182. P. 5938–5948.Zheng H., Matte-Martone C., Jain Dh., McNiff J., Shlomchik W.D. Central Memory CD8_ T Cells Induce Graft-versus-Host Disease and Mediate Graft-versus-Leukemia. The Journal of Immunology. 2009. Vol. 182. P. 5938–5948.Zhao X.Y., Wang Y. T., Mo X.D., Zhao X.S., Wang Y.Z., Chang Y. J., Huang X. J. Higher frequency of regulatory T cells in granulocyte colony-stimulating factor (G-CSF) – primed bone marrow grafts compared with G-CSF-primed peripheral blood grafts. Journal of Translational Medicine. 2015. Vol. 13. P. 145.Zhao X.Y., Wang Y. T., Mo X.D., Zhao X.S., Wang Y.Z., Chang Y. J., Huang X. J. Higher frequency of regulatory T cells in granulocyte colony-stimulating factor (G-CSF) – primed bone marrow grafts compared with G-CSF-primed peripheral blood grafts. Journal of Translational Medicine. 2015. Vol. 13. P. 145.Rezvani K., Mielke S., Ahmadzadeh M., Kilical Y., Savani B.N., Zeilah J. et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood. 2006. Vol. 108 (4). P. 1291–1297.Rezvani K., Mielke S., Ahmadzadeh M., Kilical Y., Savani B.N., Zeilah J. et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood. 2006. Vol. 108 (4). P. 1291–1297.Pabst C., Schirutschke H., Ehninger G., Bornhauser M., Platzbecker U. The graft content of donor T cells expressing gamma delta TCR+ and CD4 + foxp3+ predicts the risk of acute graft versus host disease after transplantation of allogeneic peripheral blood stem cells from unrelated donors. Clin. Cancer Res. 2007. Vol. 13 (10). P. 2916–2922.Pabst C., Schirutschke H., Ehninger G., Bornhauser M., Platzbecker U. The graft content of donor T cells expressing gamma delta TCR+ and CD4 + foxp3+ predicts the risk of acute graft versus host disease after transplantation of allogeneic peripheral blood stem cells from unrelated donors. Clin. Cancer Res. 2007. Vol. 13 (10). P. 2916–2922.Абрамов М. Г., Воробьев А.И. Костный мозг, клеточный состав // Руководство по гематологии / под ред. А.И. Воробьева. Т. 1. Москва, 2002. С. 47–53. [Abramov M.G., Vorob’ev A. I. Kostnyi mozg, kletochnyi sostav, Rukovodstvo po gematologii. A. I. Vorob’ev (ed.). Vol. 1. Moscow, 2002. P. 47–53. (In Russ.)].Абрамов М. Г., Воробьев А.И. Костный мозг, клеточный состав // Руководство по гематологии / под ред. А.И. Воробьева. Т. 1. Москва, 2002. С. 47–53. [Abramov M.G., Vorob’ev A. I. Kostnyi mozg, kletochnyi sostav, Rukovodstvo po gematologii. A. I. Vorob’ev (ed.). Vol. 1. Moscow, 2002. P. 47–53. (In Russ.)].Abrahamsen I.W., Somme S., Heldal D., Egeland T., Kvale D., Tjonnfjord G. E. Immune reconstitution after allogeneic stem cell transplantation: the impact of stem cell source and graft-versus-host-disease. Haematologica. 2005. Vol. 90. P. 86–93.Abrahamsen I.W., Somme S., Heldal D., Egeland T., Kvale D., Tjonnfjord G. E. Immune reconstitution after allogeneic stem cell transplantation: the impact of stem cell source and graft-versus-host-disease. Haematologica. 2005. Vol. 90. P. 86–93.Yamasaki S., Henzan H., Ohno Y., Yamanaka T., Iino T., Itou Y., Kuroiwa M., Maeda M., Kawano N., Kinukawa N., Miyamoto T., Nagafuji K., Shimoda K., Inaba S., Hayashi S., Taniguchi S., Shibuya T., Gondo H., Otsuka, T., Harada M., Fukuoka Blood and Marrow Transplantation Group. Influence of transplanted dose of CD56+ cells on development of graft-versus-host disease in patients receiving G-CSF-mobilized peripheral blood progenitor cells from HLA-identical sibling donors. Bone Marrow Transplantation. 2003. Vol. 32. P. 505–510.Yamasaki S., Henzan H., Ohno Y., Yamanaka T., Iino T., Itou Y., Kuroiwa M., Maeda M., Kawano N., Kinukawa N., Miyamoto T., Nagafuji K., Shimoda K., Inaba S., Hayashi S., Taniguchi S., Shibuya T., Gondo H., Otsuka, T., Harada M., Fukuoka Blood and Marrow Transplantation Group. Influence of transplanted dose of CD56+ cells on development of graft-versus-host disease in patients receiving G-CSF-mobilized peripheral blood progenitor cells from HLA-identical sibling donors. Bone Marrow Transplantation. 2003. Vol. 32. P. 505–510.Rocha V., Carmagnat M.V., Chevret S., Flinois O., Bittencourt H., Esperou H., Garnier F., Ribaud P., Devergie A., Socie G., Dal’Cortivo L., Marolleau J.P., Charron D., Gluckman E., Rabian C. Influence of bone marrow graft lymphocyte subset on the outcome of HLA-identical sibling transplants. Experimental Hematology. 2001. Vol. 29. P 1347–1352.Rocha V., Carmagnat M.V., Chevret S., Flinois O., Bittencourt H., Esperou H., Garnier F., Ribaud P., Devergie A., Socie G., Dal’Cortivo L., Marolleau J.P., Charron D., Gluckman E., Rabian C. Influence of bone marrow graft lymphocyte subset on the outcome of HLA-identical sibling transplants. Experimental Hematology. 2001. Vol. 29. P 1347–1352.

The authors declare that there are no conflicts of interest present.